Surgical aspects of non-small cell lung carcinoma

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 4, 1996, Pages 277-284

  Hooker Jr , Robert L ^a   Pompili, Mario F ^a   Mark, James B D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; CAUSE OF DEATH; ENDOSCOPY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VIDEORECORDING;

CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; COMBINED MODALITY THERAPY; ENDOSCOPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PALLIATIVE CARE; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; SURVIVAL RATE; TREATMENT OUTCOME; VIDEO RECORDING;

EID: 0030178106     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Graham EA, Singer JJ: Successful removal of an entire lung for carcinoma of the bronchus. JAMA 1933, 101:1371-1374.
2. Beahrs OH, Henson DE, Hutter RU, Myers MH, eds: American Joint Committee on Cancer Manual for Staging of Cancer. Philadelphia: JB Lippincott; 1988.
3. Strauss GM, Gleason RE, Sugarbaker DJ: Chest X-ray screening improves outcome in lung cancer. Chest 1995, 107:270S-279S. Reevaluates the data obtained from four randomized trials, initiated in the 1970s, concerning lung cancer screening. Using the American Cancer Society estimates of incidence and deaths for lung cancer along with the odds ratio for survival from the Mayo Lung Project Study (2.2), they estimate that 315,540 additional high-risk patients might have survived between 1980 and 1994 had annual chest radiographic screening been done.
4. Mulshine JL, Scott F: Molecular markers in early cancer detection. Chest 1995, 107:280S-286S.
5. Ferridno D, Buccheri G: Clinical applications of serum markers for lung cancer. Respir Med 1995, 89:507-597.
6. Colice GL, Birkmeyer JD, Black WC, Littenberg B, Silvestri G: Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 1995, 108:1264-1271.
7. Hatter J, Kohman LJ, Mosca RS, Graziano SL, Veit LJ, Coleman M: Preoperative evaluation of stage I and stage II non-small cell lung cancer. Ann Thorac Surg 1994, 58:1738-1741.
8. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, Myers RW, Lutrin CL: Staging non-small cell lung cancer by whole body positron emission tomographic imaging. Ann Thorac Surg 1995, 60:1573-1582. A prospective nonrandomized study of 99 patients evaluating the use of PET scanning for preoperative staging. Seventy-six patients underwent PET and CT scans of the mediastinum as well as surgical staging. The positive and negative predictive values for mediastinal disease were 88% and 92%, respectively, for PET and 54% and 79%, respectively, for CT scanning. The accuracy of PET scanning was 91% whereas that of CT scanning was 70%. Using whole-body scanning, 11 patients (11%) were shown to have previously undetected metastatic disease; there were no false positives.
9. Dales RE, Stark RM, Sankakaranarayanan R: Computed tomography to stage lung cancer. Am Rev Respir Dis 1990, 141:1096-1101.
10. Jolly PC, Hutchinson CH, Detterbeck F, Guyton SW, Hofer B, Anderson RP: Routine computed tomographic scans, selective mediastinoscopy, and other factors in the evaluation of lung cancer. J Thorac Cardiovasc Surg 1991, 102:266-271.
11. The Canadian Lung Oncology Group: Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surg 1995, 60:1382-1389. This multi-institutional study recruited 685 patients with operable NSCLC. Patients were randomly assigned to undergo either CT scanning or mediastinoscopy. If either study was negative the patient proceeded to thoracotomy. If the mediastinoscopy demonstrated tumor, the disease was considered unresectable. If the CT scan was positive, the patient then underwent mediastinoscopy. If these findings were also negative, the patient underwent thoracotomy. The endpoint of the study was thoracotomy without cure, ie, unresectable disease, incompletely resected disease, or recurrent tumor. The patients in the CT group were 5% less likely to undergo thoracotomy without a cure. The investigators found no benefit for mediastinoscopy without CT scan. They recommend mediastinoscopy for all patients with nodes greater than 1 cm.
12. Martini N, Flehinger BJ, Zaman MB, Beattie EJ: Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 1980, 80:390-399.
13. Pearson FG, DeLarue NC, lives R, Todd TR, Cooper JD: Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982, 83:1-11.
14. Keagy BA, Lores ME, Starek PJK, Murray GF, Lucas CL, Wilcox BR: Elective pulmonary lobectomy: factors associated with morbidity and operative mortality. Ann Thorac Surg 1985, 40:349-352.
15. Zeiher BG, Gross TJ, Kern JA, Lanza LA, Peterson MW: Predicting postoperative pulmonary function in patients undergoing lung resection. Chest 1995, 108:68-72.
16. Rao V, Todd TRJ, Kuus A, Buth KJ, Pearson FG: Exercise oximetry versus spirometry in the assessment of risk prior to lung resection. Ann Thorac Surg 1995, 60:603-609.
17. 1 and predicted postoperative DLco in the prediction of risk and mortality after pulmonary resection. Formulae were generated to estimate the probability of morbidity and mortality that can be used for guidelines and future study.
18. Bolliger CT, Wyser C, Roser H, Soler M, Perruchoud AP: Lung scanning and exercise testing for the prediction of postoperative performance in lung resection candidates at increased risk for complications. Chest 1995, 108:341-348.
19. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120-129.
20. Lung Cancer Study Group: Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg 1995, 60:615-623. Of 771 registered participants, 276 were found to be eligible for randomization and of these 247 were randomly assigned to either lobectomy or limited resection (125 and 122 patients, respectively) via thoracotomy. Six patients in the lobectomy group required mechanical ventilation for more than 24 hours postoperatively; otherwise, there was no difference between the two groups in terms of mortality and morbidity. When survival differences were considered in all 276 patients, there was no difference between the groups; however, examining the data from only the 247 there was a slightly lower death rate and death with cancer rate in the lobectomy group. There was a tripling of locoregional recurrence in the limited-resection group. The investigators did not detect any difference in late pulmonary function between the two groups.
21. Warren WH, Faber LP: Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. J Thorac Cardiovasc Surg 1994, 107:1087-1094.
22. Jacobsen MJ, Zand L, Fox RT, Lees W: A comparison of wedge and segmental resection of the lung. Thorax 1976, 31:365-368.
23. Read RC, Schaefer R, North N, Walls R: Diameter, cell type, and survival in stage I non-small cell lung cancer. Arch Surg 1988, 123:446-449.
24. Read RC, Yoder G, Schaeffer RC: Survival after conservative resection for T1 N0 M0 non-small cell lung cancer. Ann Thorac Surg 1990, 49:391-400.
25. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC: Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995, 76:787-796.
26. Landreneau RJ, Hazelrigg SR, Mack MJ, Perrino MK, Nunchuck S, Ritter PS, Defino J, Dowling RD, Keenan RJ, Ferson PF, Bowers CM, Burke D, Fitzgibbon LD: Postoperative pain-related morbidity: video-assisted thoracic surgery versus thoracotomy. Ann Thorac Surg 1993, 56:1285-1289.
27. Ferson PF, Landreneau RJ, Dowling RD, Hazelrigg SR, Magee MJ, Bowers CM, Perrino MK, Mack MJ: Thoracoscopic versus open lung biopsy for the diagnosis of diffuse infiltrative lung disease. J Thorac Cardiovasc Surg 1993, 105:194-199.
28. McKenna RJ: Lobectomy by video-assisted thoracic surgery with mediastinal node sampling for lung cancer. J Thorac Cardiovasc Surg 1994, 107:879-882.
29. Fry WA, Siddiqui A, Pensler JM, Mostafavi H: Thoracoscopic implantation of cancer with a fatal outcome. Ann Thorac Surg 1995, 59:42-45.
30. Walsh GL, Nesbitt JC: Tumor implants after thoracoscopic resection of a metastatic sarcoma. Ann Thorac Surg 1995, 59:215-216.
31. Buhr J, Hurtgen M, Kelm C, Schwemmle K: Tumor dissemination after thoracoscopic resection for lung cancer. J Thorac Cardiovasc Surg 1995, 110:855-856.
32. Mehran RJ, Deslauriers J, Piraux M, Beaulieu M, Guimont C, Brisson J: Survival related to nodal status after resection for lung cancer. J Thorac Cardiovasc Surg 1994, 107:576-583.
33. Weissberg D, Straehley CJ, Scully NM, Marguiles DR: Less than lobar resections for bronchogenic carcinoma. Scand J Thorac Cardiovasc Surg 1993, 27:121-126.
34. Remy-Jardin M, Duyck P, Remy J, Petyt L, Wurtz A, Mensier E, Copin M, Riquet M: Hilar lymph nodes: identification with spiral CT and histologic correlation. Radiology 1995, 196:387-394.
35. Paulson DL: Technical considerations in stage iii disease: the "superior sulcus" lesion. In International Trends in General Thoracic Surgery. Edited by Delarue NC, Eschapasse H. Philadelphia: WB Saunders; 1985:121-133.
36. Ginsberg RJ, Martini N, Zaman M, Armstrong JG, Bains MS, Burt ME, McCormack PM, Rusch VW, Harrison LB: Influence of surgical resection and brachytherapy in the management of superior sulcus tumor. Ann Thorac Surg 1994, 57:1440-1445.
37. McCaughan BC: Primary lung cancer invading the chest wall. Chest Surg Clin North Am 1994, 4:17-28.
38. Shah SS, Goldstraw P: Combined pulmonary and thoracic wall resection for stage III lung cancer. Thorax 1995, 50:782-784.
39. Tedder M, Anstadt MP, Tedder SD, Lowe JE: Current morbidity, mortality, and survival after bronchoplastic procedures for malignancy. Ann Thorac Surg 1992, 54:387-391.
40. Izbicki JR, Knoefel WT, Passlick B, Habekost M, Karg O, Thetter O: Risk analysis and long-term survival in patients undergoing extended resection of locally advanced lung cancer. J Thorac Cardiovasc Surg 1995, 110:386-395. This study prospectively evaluated 126 consecutive patients who underwent resections for locally advanced cancers (T3 or T4). Although patients undergoing extended resections had an increase in morbidity compared with those who did not, there was no difference between the groups in terms of mortality, severe complications, or multiple complications. Patients underwent surgery regardless of a suspicion of mediastinal organ involvement. The only patients who died (7.5%) were those who had a pneumonectomy (53%). The authors justify this approach by noting the increased survival in those who had complete resections. They did not find age to be a contraindication to an extended resection. There was no difference in survival between patients with T3 or T4 tumors or between N0 or N1 versus N2 nodal status. The best survival was in patients undergoing complete resections.
41. Miller JI: What's new in general thoracic surgery. J Am Coll Surg 1995, 182:162-169.
42. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB, Lee JS, Dhingra H, DeCaro L, Chasen M, McGavran M, Atkinson N, Hong WH: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
43. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skagel Z, Morera-Prat J, Abad A: A randomized trial comparing preoperative chemotherapy plus surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994, 330:153-158.
44. Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green MR, Cancer and Leukemia Group B Thoracic Surgery Group: Results of Cancer and Leukemia Group B protocol 8935. J Thorac Cardiovasc Surg 1995, 109:473-485. A multi-institutional phase II trial evaluating neoadjuvant chemotherapy in patients with stage IIIA disease proven by mediastinoscopy. Patients received two cycles of cisplatin and vinblastine. Patients whose disease was stable or who responded underwent thoracotomy (88%). Of the patients who underwent exploration, 75% had what appeared to be resectable lesions, but in fact only half of these were completely resectable. The patients then underwent two more cycles of chemotherapy followed by radiation. Only 45% of the patients completed the protocol. For patients who had a complete resection, there was a significant survival benefit.
45. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, Grossbard M, Lynch T, Grillo H: Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1996, 111:123-133. This is another small phase II trial with stage IIIA patients who received preoperative chemotherapy consisting of platinum, 5-fluorouracil, and vinblastine along with accelerated radiotherapy. This regimen was followed on treatment day 57 by resection. Postoperatively an additional cycle of chemotherapy and radiation was given. There was one preoperative death and two operative deaths; thus three of 40 died from the treatment. Downstaging was seen in 46%, with 14 patients total having sterilization of their N2 disease. The patients whose disease was downstaged had a significant survival benefit.
46. Rice TW, Adelstein DJ, Koka A, Tefft M, Kirby TJ, VanKirk MA, Taylor ME, Olencki TE, Peereboom D, Budd GT: Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg 1995, 60:586-592. Twenty-two patients with stages IIIA and IIIB lung cancers underwent accelerated induction therapy with cisplatin, 5-fluorouracil, and etoposide, concurrent with a fractionated radiation dose of 27 Gy. The resection rate 4 weeks later at surgery was 79%. Postoperatively the patients received a second course of chemotherapy and radiotherapy (13 to 36 Gy). There was one induction and four postoperative deaths. Despite the toxicity, there was a 40% rate of downstaging, along with excellent local control. It remains to be seen whether there is an increase in survival.
47. Ratto GB, Melioli G, Zino P, Mereu C, Mirabelli S, Fantino G, Ponte M, Minuti P, Verna A, Noceti P, Tassara E, Rovida S: Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995, 109:1212-1217.
48. Thomas P, Magnan PE, Moulin G, Giudicelli R, Fuentes P: Extended operation for lung cancer invading the superior vena cava. Eur J Cardiothorac Surg 1994, 8:177-182.
49. Dartevelle PG, Chapelier AR, Macchiarini P, Lenot B, Cerrina J, Laudrie FL, Parquin FJ, Lafont D: Anterior transcervical-thoracic approach for radical resection of lung tumors invading the thoracic inlet J Thorac Cardiovasc Surg 1993, 105:1025-1034.
50. Martini N, Yellin A, Ginsberg RJ, Bains MS, Burt ME, McCormack PM, Rusch VW: Management of non-small cell lung cancer with direct mediastinal Involvement Ann Thorac Surg 1994, 58:1447-1451.
51. Dartevelle PG, Macchiarini P, Chapelier AR: Tracheal sleeve pneumonectomy for bronchogenic carcinoma: report of 55 cases: updated in 1995. Ann Thorac Surg 1995, 60:1854-1855.
52. Kennedy L, Sahn SA: Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994, 106:1215-1222.
53. Waller DA, Morritt GN, Forty J: Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995, 107:1454-1456.
54. Gustafson G, Vicini F, Freedman L, Johnston E, Edmundson G, Sherman S, Pursel S, Komic M, Chen P, Borrego JC, Siedman J, Martinez A: High dose rate endobronchial brachytherapy in the primary and recurrent brochogenic malignancies. Cancer 1995, 75:2345-2350 This review describes a series of 46 patients treated with high-dose-rate endobronchial brachytherapy. The investigators found both clinical and radiographic response with few complications. Most patients received three treatments all done on an outpatient basis.
55. Carrasco CH, Nesbitt JC, Charnsangavej C, Ryan B, Walsh GL, Yasumori K, Lawrence DD, Wallace S: Management of tracheal and bronchial stenoses with the Gianturco stent. Ann Thorac Surg 1994, 58:1012-1017.